Dasatinib Induced Pulmonary Hypertension

Year : 2024 | Volume : 14 | Issue : 03 | Page : 92 95
    By

    Tanusha Pillai,

  • Sunitha M,

  • Ganesh N.S,

  1. Student, Department of Pharmacy, T John collage of pharmacy, Bangalore, Karnataka, India
  2. Assistant professor, Department of Pharmacy Practice, T John collage of pharmacy, Bangalore, Karnataka, India
  3. Professor and Head, Department of Pharmaceutics, T. John Collage of Pharmacy, Bangalore, Karnataka, India

Abstract

Dasatinib (Das) is a second-generation tyrosine kinase inhibitor that is used in the treatment of chronic myelogenous leukemia (CML) in patients who are resistant or intolerant to imatinib, as well as in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients. Dasatinib-induced pulmonary arterial hypertension (PAH) is a known but rare adverse effect of dasatinib and is grouped under Group-1 PAH. The mechanism of PAH development is not fully known, but there are proposed theories and experiments performed, dasatinib is a BCR-ABL1 inhibitor like imatinib and nilotinib, but it also is an Src kinase inhibitor, which could be one of the factors causing PAH. Patients with pre-existing cardiovascular or pulmonary disease may also experience pulmonary hypertension due to factors such as endothelial dysfunction and vasoconstriction. Risk factors include higher doses, prolonged treatment duration, and fluid retention, which can exacerbate pulmonary artery pressure. Regular monitoring for symptoms of PH is essential for early detection and management in patients receiving dasatinib. Usually, the symptoms resolve once the drug is discontinued. The treatment includes prostanoids like Epoprostenol 2ng/kg/min, endothelin receptor antagonists like Bosentan 62.5 mg twice daily, Ambrisentan 10 mg once daily, PDE-5 inhibitors like Sildenafil 5 mg thrice daily or Tadalafil 40 mg once in a day and guanylate cyclase stimulants like Riociguat 1 mg thrice in a day.

Keywords: Dasatinib, Pulmonary hypertension, Acute lymphoblastic leukaemia, Src kinase inhibitors, Imatinib resistant Chronic myelogenous leukaemia (CML).

[This article belongs to Research & Reviews: A Journal of Pharmacology ]

How to cite this article:
Tanusha Pillai, Sunitha M, Ganesh N.S. Dasatinib Induced Pulmonary Hypertension. Research & Reviews: A Journal of Pharmacology. 2024; 14(03):92-95.
How to cite this URL:
Tanusha Pillai, Sunitha M, Ganesh N.S. Dasatinib Induced Pulmonary Hypertension. Research & Reviews: A Journal of Pharmacology. 2024; 14(03):92-95. Available from: https://journals.stmjournals.com/rrjop/article=2024/view=191787


References

  1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal [Internet]. 2019 Jan;53(1):1801913.DOI: https://doi.org/10.1183/13993003.01913-2018
  2. Özgür Yurttaş N, Eşkazan AE. Dasatinib-induced pulmonary arterial hypertension. British Journal of Clinical Pharmacology. 2018 Mar 6;84(5):835–45.
  3. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation. 2012 May;125(17):2128–37.
  4. Pahal P, Sharma S. Secondary Pulmonary Hypertension [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526008/#:~:text=Group%202%3A%20Pulmonary%20hypertension%20secondary
  5. Hlavaty A, Roustit M, Montani D, Chaumais MC, Guignabert C, Humbert M, Cracowski JL, Khouri C. Identifying new drugs associated with pulmonary arterial hypertension: a WHO pharmacovigilance database disproportionality analysis. British Journal of Clinical Pharmacology. 2022 Dec;88(12):5227-37.
  6. McGee M, Whitehead N, Martin J, Collins N. Drug-associated pulmonary arterial hypertension. Clinical Toxicology. 2018 Sep 2;56(9):801-9.
  7. Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, Guha M, Rea D, Peacock A. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. American journal of hematology. 2015 Nov;90(11):1060-4.
  8. Eden RE, Coviello JM. Cancer, Chronic Myelogenous Leukemia (CML, Chronic Granulocytic Leukemia) [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531459/
  9. Saleh K, Fernandez A, Pasquier F. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults. Cancers. 2022 Apr 1;14(7):1805.
  10. Rinaldi I, Winston K. Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review. Journal of Blood Medicine [Internet]. 2023 Apr 1;Volume 14:261–77. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084831/
  11. Keskin D, Sadri S, Eskazan AE. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. Drug Design, Development and Therapy [Internet]. 2016 Oct [cited 2019 Nov 19];Volume 10:3355–61. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066856/
  12. Ashraf El-Dabh, Acharya D. Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors. Pulmonary circulation. 2019 Jul 29;9(3):1–6.
  13. Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid leukemia: a review. Therapeutics and Clinical Risk Management [Internet]. 2009;5:281–9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697539/
  14. Keskin D, Sadri S, Eskazan AE. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. Drug Design, Development and Therapy [Internet]. 2016 Oct [cited 2019 Nov 19];Volume 10:3355–61. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066856/
  15. Soni Savai Pullamsetti, Eva Maria Berghausen, Swati Dabral, Aleksandra Tretyn, Butrous E, Rajkumar Savai, et al. Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension. Arteriosclerosis, thrombosis, and vascular biology. 2012 Jun 1;32(6):1354–6
  16. Montani D, Seferian A, Savale L, Simonneau G, Humbert M. Drug-induced pulmonary arterial hypertension: a recent outbreak. European Respiratory Review. 2013 Aug 30;22(129):244–50.
  17. Jacobs JA, Jahangir E, Ryan JJ. Differentiating pulmonary hypertension associated with protein kinase inhibitors. Pulmonary Circulation. 2022 Apr;12(2).
  18. Guignabert C, Montani D. Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. European Respiratory Journal. 2012 Dec 31;41(1):3–4.
Regular Issue Subscription Review Article
Volume 14
Issue 03
Received 14/11/2024
Accepted 17/12/2024
Published 31/12/2024
154

Login


My IP

PlumX Metrics